Website profile

Stevens Point

Cancellations, Closures & Delays Meet Our Marketing Gurus Green Gold Fan Zone Never Forgotten Honor Flight Grand Theater 2025-26 Season ↪ How to Listen: Apps & Smart Speakers!

  • 3,558articles · 30d
  • 2+ hour agolatest article
  • Aug 15, 2026earliest in window
  • 15%with images
  • 269avg words
articles per day
Categories
  • News 1,184
  • Economy, Business & Finance 1,121
  • Politics 905
  • Finance & Business 877
  • Sports & Fitness 774
  • Sports 771
  • Sport 705
  • Sensitive Subjects 568

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Stevens Point
wsau.com > 09/11/2026 > astrazenecas-breast-cancer-drug-fails-late-stage-trial

Astrazeneca’s breast cancer drug fails late-stage trial

2+ day, 13+ hour ago   (77+ words) Sept 11 (Reuters) - ​AstraZeneca ‌said on Friday ‌its ​breast ⁠cancer ⁠drug failed ​to ⁠meet ⁠the main ​goal ​of improving ‌progression-free survival ⁠during a late-stage ⁠trial. (Reporting ‌by ⁠Christy ​Santhosh ‌in ​Bengaluru; ⁠Editing by Tasim ​Zah... Astrazeneca’s breast cancer drug fails late-stage…...

Stevens Point
wsau.com > 09/10/2026 > us-fda-pauses-new-enrollment-in-biohavens-epilepsy-drug-trials

US FDA pauses new enrollment in Biohaven’s epilepsy drug trials

3+ day, 22+ hour ago   (278+ words) Sept 10 (Reuters) – Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental ​epilepsy drug after rodent findings, sending its shares ‌down more than 13% in premarket trading. Here are…...

Stevens Point
wsau.com > 09/08/2026 > evommune-scraps-eczema-drug-after-trial-miss-shares-plunge

Evommune scraps eczema drug after trial miss, shares plunge

5+ day, 12+ hour ago   (199+ words) Sept 8 (Reuters) – Evommune said on Tuesday it will not advance its experimental skin disease drug after it ​failed to meet the main goal ‌in a mid-stage trial, sending its shares down 24% in aftermarket trading. Here are some details • The company…...

Stevens Point
wsau.com > 09/08/2026 > roivants-experimental-lung-disease-drug-meets-goals-in-mid-stage-study

Roivant’s experimental lung disease drug meets goals in mid-stage study

5+ day, 23+ hour ago   (262+ words) Sept 8 (Reuters) – Roivant said on Tuesday its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated ​with a type of lung disease, sending ‌shares up about 20% in premarket trading. Roivant has been…...

Stevens Point
wsau.com > 09/03/2026 > transgene-jumps-20-on-positive-cancer-vaccine-data-in-early-trial

Transgene jumps 20% on positive cancer vaccine data in early trial

1+ week, 4+ day ago   (191+ words) Sept 3 (Reuters) – Transgene shares surged 20% in early Paris trading on Thursday, after the French biotechnology ​company reported positive Phase 1 ‌trial data on its vaccine candidate for head and neck cancer. Investors have rewarded encouraging data from other personalised cancer-vaccine programmes…...

Stevens Point
wsau.com > 09/02/2026 > ultragenyxs-rare-disease-drug-fails-in-late-stage-trial-shares-plunge

Ultragenyx’s rare disease drug fails in late-stage trial; shares plunge

1+ week, 4+ day ago   (135+ words) Sept 2 (Reuters) – Ultragenyx Pharmaceutical said on Wednesday its experimental drug for ​a rare genetic neurodevelopmental ‌disorder did not meet the main goal in a late-stage trial, sending its shares down ‌40% ​in aftermarket ⁠trading. The drug, apazunersen, ⁠was tested as a…...

Stevens Point
wsau.com > 09/01/2026 > roche-signs-global-licensing-pact-for-simceres-experimental-blood-cancer-drug

Roche signs global licensing pact for Simcere’s experimental blood cancer drug

1+ week, 5+ day ago   (117+ words) Sept 1 (Reuters) – Switzerland’s Roche will pay $75 million upfront to Simcere Pharmaceutical Group ​for rights to an ‌experimental blood cancer drug, the Chinese drugmaker said Tuesday. • SIM0660 targets B-cell malignancies, Simcere said ‌in ​a filing ⁠to the Hong ⁠Kong stock exchange. • B…...

Stevens Point
wsau.com > 09/01/2026 > uk-regulator-suspends-amgens-tavneos-for-new-patients-over-unreliable-data

UK regulator suspends Amgen’s Tavneos for new patients over unreliable data

1+ week, 5+ day ago   (270+ words) Sept 1 (Reuters) – Britain’s medicines regulator on Tuesday suspended the use and sale of Amgen’s rare-disease drug, Tavneos, to new patients, saying the main study ​supporting its approval was unreliable. • The drug, ‌sold as Avacopan Vifor in Britain by CSL Vifor,…...

Stevens Point
wsau.com > 09/01/2026 > exclusive-us-refusals-of-crucial-newborn-vitamin-spike-raising-risk-of-dangerous-bleeding

Exclusive-US refusals of crucial newborn vitamin spike, raising risk of dangerous bleeding

1+ week, 6+ day ago   (1084+ words) CHICAGO, Sept 1 (Reuters) – The percentage of parents and caregivers in the United States refusing a standard vitamin K shot for infants at birth has accelerated sharply this year, an exclusive data analysis for Reuters found, putting more newborns at risk…...

Stevens Point
wsau.com > 09/01/2026 > astrazeneca-lung-cancer-therapy-combination-shows-promise-in-advanced-study

AstraZeneca lung cancer therapy combination shows promise in advanced study

1+ week, 6+ day ago   (94+ words) Sept 1 (Reuters) - AstraZeneca said ​on ‌Tuesday that a Chinese ‌late-stage ​trial ⁠of a ⁠combination of its cancer ​drugs Tagrisso ⁠and ⁠Orpathys ​significantly improved ​progression-free survival when ‌given as a ⁠first-line treatment for a ⁠type ‌of... AstraZeneca lung cancer therapy combination…...